Back to Authors

Sánchez‐Ferrer, Carlos F.

https://orcid.org/0000-0002-7340-3156

A5051448235 | I63634437

Mayo Clinic

Universidad Autónoma de Madrid

Citations 2

Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019)

Arteriosclerosis, Thrombosis, and Vascular Biology | November 26, 2019 | Volume: 39 | Issue: 12 | Pages: 2445-2447

10.1161/atvbaha.119.313461 | PMID 31770032

Possible modulation of release of atrial natriuretic factor by endothelium-derived relaxing factor

American Journal of Physiology-Heart and Circulatory Physiology | December 21, 2017 | Volume: 259 | Issue: 3 | Pages: H982-H986

10.1152/ajpheart.1990.259.3.h982 | PMID 2144405

The aim of the present study was to investigate the influence of inhibitors of endothelium-dependent relaxing factor on the release of atrial natriuretic factor from isolated rat atria. Electrical stimulation of the tissue produced a frequency-dependent increase in secretion of atriopeptide from basal levels. Saponin (0.3 mg/ml for 45 min) augmented the basal release of the peptide. Methylene blue (10(-5)M), oxyhemoglobin (10(-6)M), or hydroquinone (10(-5)M), agents that inhibit the effects of endothelium-derived relaxing factor by different mechanisms, caused an increase in the basal secretion of atrial natriuretic factor. Blockade of cyclooxygenase with indomethacin (10(-5)M) did not alter the release of atriopeptide, suggesting that it is not controlled by endogenous prostaglandins. These results would be explained if the inhibitors tested were to interfere with a factor released continuously from either endocardial cells or endothelial cells of the atrial blood vessels and having the same nature as endothelium-derived relaxing factor. Such release may exert a tonic negative modulatory influence on the secretion of atrial natriuretic factor.